Fig 1.
Estimation of dengue hemorrhagic fever cost of illness by estimating Direct Costs using Bottom-Up approach and Indirect Costs using Human Capital Model (Akbar et al, 2020).
Table 1.
Estimation of days of activity loss and productivity years loss depending on the level of disease and treatment modality.
Table 2.
Demographic and clinical characteristics of Source database patients (N = 717).
Table 3.
Health consumption and costs in a representative sample of confirmed dengue patients from a selection of Jeddah hospitals (Source database, N = 717).
Table 4.
Robust multivariate regression model to predict Box-Cox transformed direct costs.
Table 5.
Key results of the 5 imputations of mortality and treatment modality by severity level by year.
Fig 2.
Estimated direct and indirect costs of dengue fever in Saudi Arabia during the period 2013–2017.
Bars represent the amount in US$ of the (a) estimated direct and indirect costs by year, and (b) different components of indirect costs including costs related to daily activity loss (DALS), caregiver daily activity loss (CG-DALS) and productivity years loss (PYLS).
Table 6.
Estimated dengue costs in Saudi Arabia during the period 2013–2017.
Table 7.
Estimated dengue costs in Saudi Arabia during the period 2013–2017 including the correction for under-reporting.